Why BioHaven Stock Is Soaring Today

Shares of Biohaven (NYSE: BHVN) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 traded mixed and the Nasdaq Composite drifted slightly higher.

Shares of the clinical-stage biopharmaceutical company were rising after Biohaven announced a $600 million non-dilutive financing deal with Oberland Capital.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

A big cash infusion

Biohaven revealed it has secured up to $600 million from the investment firm Oberland Capital Management. The deal includes an immediate $250 million with the remainder tied to regulatory milestones and strategic acquisitions. Critically, the deal is non-dilutive, meaning that Oberland doesn't get new shares -- a move that would reduce the value of existing shareholders' portfolios. Announced via press release, the deal provides "significant financial resources" to advance clinical trials and prepare for a potential FDA approval of troriluzole for spinocerebellar ataxia (SCA).

Troriluzole is Biohaven's lead candidate for SCA, a rare, fatal neurological condition with no approved therapies. Today's funding gives Biohaven significant runway to complete its late-stage development. The company is pre-revenue and relies on investment to develop its treatments; this cash allows the company to continue investing across its pipeline of drugs that includes treatments for oncology and immunology.

Biohaven is still seeking final approval

At around a $3 billion market cap pre-news, Biohaven isn't cheap for a pre-revenue biotech, but the non-dilutive $600 million infusion adds a big safety cushion. If troriluzole gains FDA approval, its valuation will make more sense. This is by no means a guarantee though, nor is any timeline. Regulatory setbacks remain a big risk. Still, its SCA treatment looks promising. If you have a high risk tolerance, Biohaven's stock could pay off.

Should you invest $1,000 in Biohaven right now?

Before you buy stock in Biohaven, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biohaven wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $680,390!*

Now, it’s worth noting Stock Advisor’s total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 28, 2025

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.